NCT05860608

Multidisciplinary Approach for High-risk Patients Leading to Early Diagnosis of Canadians With Heart Failure

Multidisciplinary Approach for High-risk Patients Leading to Early Diagnosis of Canadians With Heart Failure.

• Status: Withdrawn
• Phase: N/A
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Montreal Heart Institute · Academic / Other
• Sex: All
• Age: 40 Years
• Healthy volunteers: Not accepted

Summary

In the MAPLE-CHF trial, patients will be screened for HF risk factors using electronic medical records of participating family physicians to identify patients with potentially undiagnosed HF. Participants will then undergo a diagnostic evaluation using a blood sample for a hormone specific to the heart, the natriuretic peptide or NT-proBNP; if elevated, a portable cardiac ultrasound (ECHO) with artificial intelligence (AI) interpretation will be done; both NT-proBNP and ECHO are required for diagnosis in patients with signs and symptoms suggestive of HF. This screening ECHO coupled with AI reading from Us2.ai provides a fast, reliable, and inexpensive report, which is particularly important in our context, where waiting lists for such examinations can reach up to one year.

Conditions

• Heart Failure

Interventions

Type	Name	Description
DEVICE	Us2.ai (AI-enabled report) handheld echocardiogram	NT-proBNP will be performed in all individuals randomized to the ACTIVE arm at the same visit as informed consent, and those with elevated NT-proBNP (≥125pg/ml) will be invited to attend a visit for an Us2.ai (AI-enabled) echocardiogram which will be controlled with a standard echocardiographic study if the AI-echo is non-diagnostic.

Timeline

• Start date: 2024-11-20
• Primary completion: 2024-11-20
• Completion: 2024-11-20
• First posted: 2023-05-16
• Last updated: 2024-11-22

Locations

2 sites across 1 country: Canada